nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—MPO—urinary bladder cancer	0.219	0.442	CbGaD
Mesalazine—PPARG—urinary bladder cancer	0.194	0.392	CbGaD
Mesalazine—MPO—Carboplatin—urinary bladder cancer	0.0908	0.373	CbGbCtD
Mesalazine—PTGS2—urinary bladder cancer	0.082	0.166	CbGaD
Mesalazine—MPO—Cisplatin—urinary bladder cancer	0.0776	0.318	CbGbCtD
Mesalazine—PTGS2—Cisplatin—urinary bladder cancer	0.0268	0.11	CbGbCtD
Mesalazine—PTGS2—Etoposide—urinary bladder cancer	0.0263	0.108	CbGbCtD
Mesalazine—PTGS1—Etoposide—urinary bladder cancer	0.0222	0.0912	CbGbCtD
Mesalazine—CHUK—prostate gland—urinary bladder cancer	0.00289	0.076	CbGeAlD
Mesalazine—CHUK—epithelium—urinary bladder cancer	0.00212	0.0559	CbGeAlD
Mesalazine—CHUK—renal system—urinary bladder cancer	0.00197	0.0518	CbGeAlD
Mesalazine—IKBKB—prostate gland—urinary bladder cancer	0.00196	0.0517	CbGeAlD
Mesalazine—ALOX5—prostate gland—urinary bladder cancer	0.00163	0.0428	CbGeAlD
Mesalazine—CHUK—female reproductive system—urinary bladder cancer	0.00158	0.0415	CbGeAlD
Mesalazine—PPARG—Teniposide—Etoposide—urinary bladder cancer	0.00151	1	CbGdCrCtD
Mesalazine—IKBKB—smooth muscle tissue—urinary bladder cancer	0.00139	0.0366	CbGeAlD
Mesalazine—IKBKB—urethra—urinary bladder cancer	0.00132	0.0346	CbGeAlD
Mesalazine—PPARG—prostate gland—urinary bladder cancer	0.00122	0.0322	CbGeAlD
Mesalazine—ALOX5—smooth muscle tissue—urinary bladder cancer	0.00115	0.0303	CbGeAlD
Mesalazine—ALOX5—urethra—urinary bladder cancer	0.00109	0.0287	CbGeAlD
Mesalazine—IKBKB—female reproductive system—urinary bladder cancer	0.00107	0.0282	CbGeAlD
Mesalazine—MPO—epithelium—urinary bladder cancer	0.00101	0.0266	CbGeAlD
Mesalazine—IKBKB—vagina—urinary bladder cancer	0.00097	0.0255	CbGeAlD
Mesalazine—MPO—renal system—urinary bladder cancer	0.000939	0.0247	CbGeAlD
Mesalazine—CHUK—lymph node—urinary bladder cancer	0.000923	0.0243	CbGeAlD
Mesalazine—PPARG—epithelium—urinary bladder cancer	0.000898	0.0236	CbGeAlD
Mesalazine—ALOX5—female reproductive system—urinary bladder cancer	0.000889	0.0234	CbGeAlD
Mesalazine—PPARG—smooth muscle tissue—urinary bladder cancer	0.000865	0.0228	CbGeAlD
Mesalazine—PPARG—renal system—urinary bladder cancer	0.000833	0.0219	CbGeAlD
Mesalazine—PPARG—urethra—urinary bladder cancer	0.000818	0.0215	CbGeAlD
Mesalazine—PPARG—female reproductive system—urinary bladder cancer	0.000667	0.0176	CbGeAlD
Mesalazine—Aminosalicylic Acid—MPO—urinary bladder cancer	0.000656	0.258	CrCbGaD
Mesalazine—PTGS1—prostate gland—urinary bladder cancer	0.000653	0.0172	CbGeAlD
Mesalazine—IKBKB—lymph node—urinary bladder cancer	0.000627	0.0165	CbGeAlD
Mesalazine—PTGS2—prostate gland—urinary bladder cancer	0.000625	0.0164	CbGeAlD
Mesalazine—Olsalazine—PPARG—urinary bladder cancer	0.00062	0.243	CrCbGaD
Mesalazine—PPARG—vagina—urinary bladder cancer	0.000603	0.0159	CbGeAlD
Mesalazine—PTGS1—seminal vesicle—urinary bladder cancer	0.000553	0.0145	CbGeAlD
Mesalazine—PTGS2—seminal vesicle—urinary bladder cancer	0.000528	0.0139	CbGeAlD
Mesalazine—ALOX5—lymph node—urinary bladder cancer	0.00052	0.0137	CbGeAlD
Mesalazine—PTGS1—epithelium—urinary bladder cancer	0.00048	0.0126	CbGeAlD
Mesalazine—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000463	0.0122	CbGeAlD
Mesalazine—PTGS2—epithelium—urinary bladder cancer	0.000459	0.0121	CbGeAlD
Mesalazine—PTGS1—renal system—urinary bladder cancer	0.000445	0.0117	CbGeAlD
Mesalazine—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000442	0.0116	CbGeAlD
Mesalazine—MPO—lymph node—urinary bladder cancer	0.00044	0.0116	CbGeAlD
Mesalazine—PTGS2—renal system—urinary bladder cancer	0.000426	0.0112	CbGeAlD
Mesalazine—PTGS2—urethra—urinary bladder cancer	0.000418	0.011	CbGeAlD
Mesalazine—PPARG—lymph node—urinary bladder cancer	0.00039	0.0103	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS2—urinary bladder cancer	0.000382	0.15	CrCbGaD
Mesalazine—PTGS1—female reproductive system—urinary bladder cancer	0.000357	0.00938	CbGeAlD
Mesalazine—PTGS2—female reproductive system—urinary bladder cancer	0.000341	0.00897	CbGeAlD
Mesalazine—PTGS1—vagina—urinary bladder cancer	0.000323	0.00849	CbGeAlD
Mesalazine—PTGS2—vagina—urinary bladder cancer	0.000308	0.00811	CbGeAlD
Mesalazine—Olsalazine—PTGS2—urinary bladder cancer	0.000262	0.103	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS2—urinary bladder cancer	0.000246	0.0965	CrCbGaD
Mesalazine—Diflunisal—PTGS2—urinary bladder cancer	0.000246	0.0965	CrCbGaD
Mesalazine—PTGS1—lymph node—urinary bladder cancer	0.000209	0.00549	CbGeAlD
Mesalazine—PTGS2—lymph node—urinary bladder cancer	0.000199	0.00525	CbGeAlD
Mesalazine—Salicylic acid—PTGS2—urinary bladder cancer	0.000137	0.0537	CrCbGaD
Mesalazine—Tinnitus—Methotrexate—urinary bladder cancer	4.24e-05	0.000332	CcSEcCtD
Mesalazine—Asthenia—Cisplatin—urinary bladder cancer	4.22e-05	0.00033	CcSEcCtD
Mesalazine—Pharyngitis—Epirubicin—urinary bladder cancer	4.22e-05	0.00033	CcSEcCtD
Mesalazine—Cardiac disorder—Methotrexate—urinary bladder cancer	4.22e-05	0.00033	CcSEcCtD
Mesalazine—Sweating—Doxorubicin—urinary bladder cancer	4.2e-05	0.000329	CcSEcCtD
Mesalazine—Urinary tract disorder—Epirubicin—urinary bladder cancer	4.2e-05	0.000329	CcSEcCtD
Mesalazine—Oedema peripheral—Epirubicin—urinary bladder cancer	4.19e-05	0.000328	CcSEcCtD
Mesalazine—Haematuria—Doxorubicin—urinary bladder cancer	4.18e-05	0.000327	CcSEcCtD
Mesalazine—Connective tissue disorder—Epirubicin—urinary bladder cancer	4.18e-05	0.000327	CcSEcCtD
Mesalazine—Urethral disorder—Epirubicin—urinary bladder cancer	4.17e-05	0.000326	CcSEcCtD
Mesalazine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	4.15e-05	0.000324	CcSEcCtD
Mesalazine—Epistaxis—Doxorubicin—urinary bladder cancer	4.14e-05	0.000324	CcSEcCtD
Mesalazine—Angiopathy—Methotrexate—urinary bladder cancer	4.12e-05	0.000323	CcSEcCtD
Mesalazine—Sinusitis—Doxorubicin—urinary bladder cancer	4.11e-05	0.000322	CcSEcCtD
Mesalazine—Immune system disorder—Methotrexate—urinary bladder cancer	4.11e-05	0.000321	CcSEcCtD
Mesalazine—Dizziness—Fluorouracil—urinary bladder cancer	4.11e-05	0.000321	CcSEcCtD
Mesalazine—Mediastinal disorder—Methotrexate—urinary bladder cancer	4.1e-05	0.00032	CcSEcCtD
Mesalazine—Agranulocytosis—Doxorubicin—urinary bladder cancer	4.09e-05	0.00032	CcSEcCtD
Mesalazine—Chills—Methotrexate—urinary bladder cancer	4.08e-05	0.000319	CcSEcCtD
Mesalazine—Diarrhoea—Cisplatin—urinary bladder cancer	4.03e-05	0.000315	CcSEcCtD
Mesalazine—Erythema multiforme—Epirubicin—urinary bladder cancer	4.02e-05	0.000315	CcSEcCtD
Mesalazine—Alopecia—Methotrexate—urinary bladder cancer	4.02e-05	0.000314	CcSEcCtD
Mesalazine—Vomiting—Gemcitabine—urinary bladder cancer	4.01e-05	0.000314	CcSEcCtD
Mesalazine—Mental disorder—Methotrexate—urinary bladder cancer	3.98e-05	0.000312	CcSEcCtD
Mesalazine—Rash—Gemcitabine—urinary bladder cancer	3.98e-05	0.000311	CcSEcCtD
Mesalazine—Dermatitis—Gemcitabine—urinary bladder cancer	3.98e-05	0.000311	CcSEcCtD
Mesalazine—Eye disorder—Epirubicin—urinary bladder cancer	3.98e-05	0.000311	CcSEcCtD
Mesalazine—Hypersensitivity—Etoposide—urinary bladder cancer	3.97e-05	0.000311	CcSEcCtD
Mesalazine—Tinnitus—Epirubicin—urinary bladder cancer	3.97e-05	0.00031	CcSEcCtD
Mesalazine—Erythema—Methotrexate—urinary bladder cancer	3.96e-05	0.00031	CcSEcCtD
Mesalazine—Haemoglobin—Doxorubicin—urinary bladder cancer	3.96e-05	0.000309	CcSEcCtD
Mesalazine—Headache—Gemcitabine—urinary bladder cancer	3.96e-05	0.000309	CcSEcCtD
Mesalazine—Cardiac disorder—Epirubicin—urinary bladder cancer	3.95e-05	0.000309	CcSEcCtD
Mesalazine—Vomiting—Fluorouracil—urinary bladder cancer	3.95e-05	0.000309	CcSEcCtD
Mesalazine—Rhinitis—Doxorubicin—urinary bladder cancer	3.95e-05	0.000309	CcSEcCtD
Mesalazine—Haemorrhage—Doxorubicin—urinary bladder cancer	3.94e-05	0.000308	CcSEcCtD
Mesalazine—Hepatitis—Doxorubicin—urinary bladder cancer	3.94e-05	0.000308	CcSEcCtD
Mesalazine—Rash—Fluorouracil—urinary bladder cancer	3.91e-05	0.000306	CcSEcCtD
Mesalazine—Dermatitis—Fluorouracil—urinary bladder cancer	3.91e-05	0.000306	CcSEcCtD
Mesalazine—Pharyngitis—Doxorubicin—urinary bladder cancer	3.91e-05	0.000306	CcSEcCtD
Mesalazine—Headache—Fluorouracil—urinary bladder cancer	3.89e-05	0.000304	CcSEcCtD
Mesalazine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	3.89e-05	0.000304	CcSEcCtD
Mesalazine—Oedema peripheral—Doxorubicin—urinary bladder cancer	3.88e-05	0.000303	CcSEcCtD
Mesalazine—Dysgeusia—Methotrexate—urinary bladder cancer	3.88e-05	0.000303	CcSEcCtD
Mesalazine—Asthenia—Etoposide—urinary bladder cancer	3.87e-05	0.000303	CcSEcCtD
Mesalazine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	3.87e-05	0.000303	CcSEcCtD
Mesalazine—Angiopathy—Epirubicin—urinary bladder cancer	3.86e-05	0.000302	CcSEcCtD
Mesalazine—Urethral disorder—Doxorubicin—urinary bladder cancer	3.86e-05	0.000302	CcSEcCtD
Mesalazine—Immune system disorder—Epirubicin—urinary bladder cancer	3.84e-05	0.000301	CcSEcCtD
Mesalazine—Mediastinal disorder—Epirubicin—urinary bladder cancer	3.83e-05	0.0003	CcSEcCtD
Mesalazine—Back pain—Methotrexate—urinary bladder cancer	3.83e-05	0.000299	CcSEcCtD
Mesalazine—Chills—Epirubicin—urinary bladder cancer	3.82e-05	0.000299	CcSEcCtD
Mesalazine—Pruritus—Etoposide—urinary bladder cancer	3.81e-05	0.000298	CcSEcCtD
Mesalazine—Alopecia—Epirubicin—urinary bladder cancer	3.76e-05	0.000294	CcSEcCtD
Mesalazine—Nausea—Gemcitabine—urinary bladder cancer	3.75e-05	0.000293	CcSEcCtD
Mesalazine—Vomiting—Cisplatin—urinary bladder cancer	3.74e-05	0.000293	CcSEcCtD
Mesalazine—Vision blurred—Methotrexate—urinary bladder cancer	3.73e-05	0.000292	CcSEcCtD
Mesalazine—Mental disorder—Epirubicin—urinary bladder cancer	3.73e-05	0.000292	CcSEcCtD
Mesalazine—Erythema multiforme—Doxorubicin—urinary bladder cancer	3.72e-05	0.000291	CcSEcCtD
Mesalazine—Rash—Cisplatin—urinary bladder cancer	3.71e-05	0.00029	CcSEcCtD
Mesalazine—Dermatitis—Cisplatin—urinary bladder cancer	3.71e-05	0.00029	CcSEcCtD
Mesalazine—Erythema—Epirubicin—urinary bladder cancer	3.7e-05	0.00029	CcSEcCtD
Mesalazine—Diarrhoea—Etoposide—urinary bladder cancer	3.69e-05	0.000289	CcSEcCtD
Mesalazine—Nausea—Fluorouracil—urinary bladder cancer	3.69e-05	0.000288	CcSEcCtD
Mesalazine—Eye disorder—Doxorubicin—urinary bladder cancer	3.68e-05	0.000288	CcSEcCtD
Mesalazine—Ill-defined disorder—Methotrexate—urinary bladder cancer	3.67e-05	0.000287	CcSEcCtD
Mesalazine—Tinnitus—Doxorubicin—urinary bladder cancer	3.67e-05	0.000287	CcSEcCtD
Mesalazine—Anaemia—Methotrexate—urinary bladder cancer	3.66e-05	0.000286	CcSEcCtD
Mesalazine—Cardiac disorder—Doxorubicin—urinary bladder cancer	3.65e-05	0.000286	CcSEcCtD
Mesalazine—Flatulence—Epirubicin—urinary bladder cancer	3.65e-05	0.000285	CcSEcCtD
Mesalazine—Tension—Epirubicin—urinary bladder cancer	3.63e-05	0.000284	CcSEcCtD
Mesalazine—Dysgeusia—Epirubicin—urinary bladder cancer	3.63e-05	0.000284	CcSEcCtD
Mesalazine—Nervousness—Epirubicin—urinary bladder cancer	3.6e-05	0.000281	CcSEcCtD
Mesalazine—Back pain—Epirubicin—urinary bladder cancer	3.58e-05	0.00028	CcSEcCtD
Mesalazine—Angiopathy—Doxorubicin—urinary bladder cancer	3.57e-05	0.000279	CcSEcCtD
Mesalazine—Malaise—Methotrexate—urinary bladder cancer	3.57e-05	0.000279	CcSEcCtD
Mesalazine—Dizziness—Etoposide—urinary bladder cancer	3.57e-05	0.000279	CcSEcCtD
Mesalazine—Muscle spasms—Epirubicin—urinary bladder cancer	3.56e-05	0.000279	CcSEcCtD
Mesalazine—Immune system disorder—Doxorubicin—urinary bladder cancer	3.56e-05	0.000278	CcSEcCtD
Mesalazine—Vertigo—Methotrexate—urinary bladder cancer	3.56e-05	0.000278	CcSEcCtD
Mesalazine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	3.55e-05	0.000277	CcSEcCtD
Mesalazine—Leukopenia—Methotrexate—urinary bladder cancer	3.54e-05	0.000277	CcSEcCtD
Mesalazine—Chills—Doxorubicin—urinary bladder cancer	3.53e-05	0.000276	CcSEcCtD
Mesalazine—Nausea—Cisplatin—urinary bladder cancer	3.5e-05	0.000273	CcSEcCtD
Mesalazine—Vision blurred—Epirubicin—urinary bladder cancer	3.49e-05	0.000273	CcSEcCtD
Mesalazine—Alopecia—Doxorubicin—urinary bladder cancer	3.48e-05	0.000272	CcSEcCtD
Mesalazine—Cough—Methotrexate—urinary bladder cancer	3.45e-05	0.00027	CcSEcCtD
Mesalazine—Mental disorder—Doxorubicin—urinary bladder cancer	3.45e-05	0.00027	CcSEcCtD
Mesalazine—Ill-defined disorder—Epirubicin—urinary bladder cancer	3.44e-05	0.000269	CcSEcCtD
Mesalazine—Vomiting—Etoposide—urinary bladder cancer	3.43e-05	0.000268	CcSEcCtD
Mesalazine—Erythema—Doxorubicin—urinary bladder cancer	3.43e-05	0.000268	CcSEcCtD
Mesalazine—Anaemia—Epirubicin—urinary bladder cancer	3.42e-05	0.000268	CcSEcCtD
Mesalazine—Rash—Etoposide—urinary bladder cancer	3.4e-05	0.000266	CcSEcCtD
Mesalazine—Dermatitis—Etoposide—urinary bladder cancer	3.4e-05	0.000266	CcSEcCtD
Mesalazine—Headache—Etoposide—urinary bladder cancer	3.38e-05	0.000264	CcSEcCtD
Mesalazine—Flatulence—Doxorubicin—urinary bladder cancer	3.38e-05	0.000264	CcSEcCtD
Mesalazine—Chest pain—Methotrexate—urinary bladder cancer	3.37e-05	0.000264	CcSEcCtD
Mesalazine—Myalgia—Methotrexate—urinary bladder cancer	3.37e-05	0.000264	CcSEcCtD
Mesalazine—Arthralgia—Methotrexate—urinary bladder cancer	3.37e-05	0.000264	CcSEcCtD
Mesalazine—Tension—Doxorubicin—urinary bladder cancer	3.36e-05	0.000263	CcSEcCtD
Mesalazine—Dysgeusia—Doxorubicin—urinary bladder cancer	3.36e-05	0.000262	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	3.35e-05	0.000262	CcSEcCtD
Mesalazine—Malaise—Epirubicin—urinary bladder cancer	3.34e-05	0.000261	CcSEcCtD
Mesalazine—Discomfort—Methotrexate—urinary bladder cancer	3.33e-05	0.00026	CcSEcCtD
Mesalazine—Nervousness—Doxorubicin—urinary bladder cancer	3.33e-05	0.00026	CcSEcCtD
Mesalazine—Vertigo—Epirubicin—urinary bladder cancer	3.33e-05	0.00026	CcSEcCtD
Mesalazine—Syncope—Epirubicin—urinary bladder cancer	3.32e-05	0.00026	CcSEcCtD
Mesalazine—Leukopenia—Epirubicin—urinary bladder cancer	3.31e-05	0.000259	CcSEcCtD
Mesalazine—Back pain—Doxorubicin—urinary bladder cancer	3.31e-05	0.000259	CcSEcCtD
Mesalazine—Muscle spasms—Doxorubicin—urinary bladder cancer	3.29e-05	0.000258	CcSEcCtD
Mesalazine—Palpitations—Epirubicin—urinary bladder cancer	3.27e-05	0.000256	CcSEcCtD
Mesalazine—Confusional state—Methotrexate—urinary bladder cancer	3.26e-05	0.000255	CcSEcCtD
Mesalazine—Loss of consciousness—Epirubicin—urinary bladder cancer	3.25e-05	0.000255	CcSEcCtD
Mesalazine—Cough—Epirubicin—urinary bladder cancer	3.23e-05	0.000253	CcSEcCtD
Mesalazine—Anaphylactic shock—Methotrexate—urinary bladder cancer	3.23e-05	0.000253	CcSEcCtD
Mesalazine—Vision blurred—Doxorubicin—urinary bladder cancer	3.23e-05	0.000253	CcSEcCtD
Mesalazine—Infection—Methotrexate—urinary bladder cancer	3.21e-05	0.000251	CcSEcCtD
Mesalazine—Nausea—Etoposide—urinary bladder cancer	3.2e-05	0.000251	CcSEcCtD
Mesalazine—Hypertension—Epirubicin—urinary bladder cancer	3.2e-05	0.00025	CcSEcCtD
Mesalazine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	3.18e-05	0.000249	CcSEcCtD
Mesalazine—Nervous system disorder—Methotrexate—urinary bladder cancer	3.17e-05	0.000248	CcSEcCtD
Mesalazine—Anaemia—Doxorubicin—urinary bladder cancer	3.17e-05	0.000248	CcSEcCtD
Mesalazine—Thrombocytopenia—Methotrexate—urinary bladder cancer	3.16e-05	0.000247	CcSEcCtD
Mesalazine—Arthralgia—Epirubicin—urinary bladder cancer	3.15e-05	0.000247	CcSEcCtD
Mesalazine—Chest pain—Epirubicin—urinary bladder cancer	3.15e-05	0.000247	CcSEcCtD
Mesalazine—Myalgia—Epirubicin—urinary bladder cancer	3.15e-05	0.000247	CcSEcCtD
Mesalazine—Anxiety—Epirubicin—urinary bladder cancer	3.14e-05	0.000246	CcSEcCtD
Mesalazine—Skin disorder—Methotrexate—urinary bladder cancer	3.14e-05	0.000245	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	3.13e-05	0.000245	CcSEcCtD
Mesalazine—Hyperhidrosis—Methotrexate—urinary bladder cancer	3.12e-05	0.000244	CcSEcCtD
Mesalazine—Discomfort—Epirubicin—urinary bladder cancer	3.12e-05	0.000244	CcSEcCtD
Mesalazine—Malaise—Doxorubicin—urinary bladder cancer	3.09e-05	0.000242	CcSEcCtD
Mesalazine—Dry mouth—Epirubicin—urinary bladder cancer	3.08e-05	0.000241	CcSEcCtD
Mesalazine—Vertigo—Doxorubicin—urinary bladder cancer	3.08e-05	0.000241	CcSEcCtD
Mesalazine—Anorexia—Methotrexate—urinary bladder cancer	3.08e-05	0.000241	CcSEcCtD
Mesalazine—Syncope—Doxorubicin—urinary bladder cancer	3.07e-05	0.00024	CcSEcCtD
Mesalazine—Leukopenia—Doxorubicin—urinary bladder cancer	3.07e-05	0.00024	CcSEcCtD
Mesalazine—Confusional state—Epirubicin—urinary bladder cancer	3.05e-05	0.000238	CcSEcCtD
Mesalazine—Palpitations—Doxorubicin—urinary bladder cancer	3.03e-05	0.000237	CcSEcCtD
Mesalazine—Anaphylactic shock—Epirubicin—urinary bladder cancer	3.02e-05	0.000236	CcSEcCtD
Mesalazine—Oedema—Epirubicin—urinary bladder cancer	3.02e-05	0.000236	CcSEcCtD
Mesalazine—Hypotension—Methotrexate—urinary bladder cancer	3.02e-05	0.000236	CcSEcCtD
Mesalazine—Loss of consciousness—Doxorubicin—urinary bladder cancer	3.01e-05	0.000236	CcSEcCtD
Mesalazine—Infection—Epirubicin—urinary bladder cancer	3e-05	0.000235	CcSEcCtD
Mesalazine—Cough—Doxorubicin—urinary bladder cancer	2.99e-05	0.000234	CcSEcCtD
Mesalazine—Shock—Epirubicin—urinary bladder cancer	2.97e-05	0.000233	CcSEcCtD
Mesalazine—Nervous system disorder—Epirubicin—urinary bladder cancer	2.96e-05	0.000232	CcSEcCtD
Mesalazine—Thrombocytopenia—Epirubicin—urinary bladder cancer	2.96e-05	0.000231	CcSEcCtD
Mesalazine—Hypertension—Doxorubicin—urinary bladder cancer	2.96e-05	0.000231	CcSEcCtD
Mesalazine—Tachycardia—Epirubicin—urinary bladder cancer	2.95e-05	0.000231	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	2.94e-05	0.00023	CcSEcCtD
Mesalazine—Skin disorder—Epirubicin—urinary bladder cancer	2.94e-05	0.00023	CcSEcCtD
Mesalazine—Hyperhidrosis—Epirubicin—urinary bladder cancer	2.92e-05	0.000229	CcSEcCtD
Mesalazine—Insomnia—Methotrexate—urinary bladder cancer	2.92e-05	0.000228	CcSEcCtD
Mesalazine—Myalgia—Doxorubicin—urinary bladder cancer	2.92e-05	0.000228	CcSEcCtD
Mesalazine—Chest pain—Doxorubicin—urinary bladder cancer	2.92e-05	0.000228	CcSEcCtD
Mesalazine—Arthralgia—Doxorubicin—urinary bladder cancer	2.92e-05	0.000228	CcSEcCtD
Mesalazine—Anxiety—Doxorubicin—urinary bladder cancer	2.91e-05	0.000227	CcSEcCtD
Mesalazine—Paraesthesia—Methotrexate—urinary bladder cancer	2.9e-05	0.000227	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	2.9e-05	0.000227	CcSEcCtD
Mesalazine—Discomfort—Doxorubicin—urinary bladder cancer	2.88e-05	0.000225	CcSEcCtD
Mesalazine—Anorexia—Epirubicin—urinary bladder cancer	2.88e-05	0.000225	CcSEcCtD
Mesalazine—Dyspnoea—Methotrexate—urinary bladder cancer	2.88e-05	0.000225	CcSEcCtD
Mesalazine—Somnolence—Methotrexate—urinary bladder cancer	2.87e-05	0.000225	CcSEcCtD
Mesalazine—Dry mouth—Doxorubicin—urinary bladder cancer	2.85e-05	0.000223	CcSEcCtD
Mesalazine—Dyspepsia—Methotrexate—urinary bladder cancer	2.84e-05	0.000222	CcSEcCtD
Mesalazine—Hypotension—Epirubicin—urinary bladder cancer	2.82e-05	0.000221	CcSEcCtD
Mesalazine—Confusional state—Doxorubicin—urinary bladder cancer	2.82e-05	0.000221	CcSEcCtD
Mesalazine—Decreased appetite—Methotrexate—urinary bladder cancer	2.81e-05	0.00022	CcSEcCtD
Mesalazine—Oedema—Doxorubicin—urinary bladder cancer	2.8e-05	0.000219	CcSEcCtD
Mesalazine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	2.8e-05	0.000219	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	2.79e-05	0.000218	CcSEcCtD
Mesalazine—Fatigue—Methotrexate—urinary bladder cancer	2.78e-05	0.000218	CcSEcCtD
Mesalazine—Infection—Doxorubicin—urinary bladder cancer	2.78e-05	0.000217	CcSEcCtD
Mesalazine—Pain—Methotrexate—urinary bladder cancer	2.76e-05	0.000216	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	2.75e-05	0.000215	CcSEcCtD
Mesalazine—Shock—Doxorubicin—urinary bladder cancer	2.75e-05	0.000215	CcSEcCtD
Mesalazine—Nervous system disorder—Doxorubicin—urinary bladder cancer	2.74e-05	0.000215	CcSEcCtD
Mesalazine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	2.74e-05	0.000214	CcSEcCtD
Mesalazine—Insomnia—Epirubicin—urinary bladder cancer	2.73e-05	0.000214	CcSEcCtD
Mesalazine—Tachycardia—Doxorubicin—urinary bladder cancer	2.73e-05	0.000213	CcSEcCtD
Mesalazine—Skin disorder—Doxorubicin—urinary bladder cancer	2.72e-05	0.000212	CcSEcCtD
Mesalazine—Paraesthesia—Epirubicin—urinary bladder cancer	2.71e-05	0.000212	CcSEcCtD
Mesalazine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	2.7e-05	0.000211	CcSEcCtD
Mesalazine—Dyspnoea—Epirubicin—urinary bladder cancer	2.69e-05	0.000211	CcSEcCtD
Mesalazine—Somnolence—Epirubicin—urinary bladder cancer	2.69e-05	0.00021	CcSEcCtD
Mesalazine—Anorexia—Doxorubicin—urinary bladder cancer	2.67e-05	0.000209	CcSEcCtD
Mesalazine—Feeling abnormal—Methotrexate—urinary bladder cancer	2.66e-05	0.000208	CcSEcCtD
Mesalazine—Dyspepsia—Epirubicin—urinary bladder cancer	2.66e-05	0.000208	CcSEcCtD
Mesalazine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	2.64e-05	0.000207	CcSEcCtD
Mesalazine—Decreased appetite—Epirubicin—urinary bladder cancer	2.63e-05	0.000206	CcSEcCtD
Mesalazine—Hypotension—Doxorubicin—urinary bladder cancer	2.61e-05	0.000204	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	2.61e-05	0.000204	CcSEcCtD
Mesalazine—Fatigue—Epirubicin—urinary bladder cancer	2.61e-05	0.000204	CcSEcCtD
Mesalazine—Pain—Epirubicin—urinary bladder cancer	2.58e-05	0.000202	CcSEcCtD
Mesalazine—Constipation—Epirubicin—urinary bladder cancer	2.58e-05	0.000202	CcSEcCtD
Mesalazine—Urticaria—Methotrexate—urinary bladder cancer	2.57e-05	0.000201	CcSEcCtD
Mesalazine—Abdominal pain—Methotrexate—urinary bladder cancer	2.55e-05	0.0002	CcSEcCtD
Mesalazine—Body temperature increased—Methotrexate—urinary bladder cancer	2.55e-05	0.0002	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	2.55e-05	0.000199	CcSEcCtD
Mesalazine—Insomnia—Doxorubicin—urinary bladder cancer	2.53e-05	0.000198	CcSEcCtD
Mesalazine—Paraesthesia—Doxorubicin—urinary bladder cancer	2.51e-05	0.000196	CcSEcCtD
Mesalazine—Dyspnoea—Doxorubicin—urinary bladder cancer	2.49e-05	0.000195	CcSEcCtD
Mesalazine—Feeling abnormal—Epirubicin—urinary bladder cancer	2.49e-05	0.000195	CcSEcCtD
Mesalazine—Somnolence—Doxorubicin—urinary bladder cancer	2.49e-05	0.000194	CcSEcCtD
Mesalazine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.47e-05	0.000193	CcSEcCtD
Mesalazine—Dyspepsia—Doxorubicin—urinary bladder cancer	2.46e-05	0.000193	CcSEcCtD
Mesalazine—Decreased appetite—Doxorubicin—urinary bladder cancer	2.43e-05	0.00019	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2.41e-05	0.000189	CcSEcCtD
Mesalazine—Fatigue—Doxorubicin—urinary bladder cancer	2.41e-05	0.000189	CcSEcCtD
Mesalazine—Urticaria—Epirubicin—urinary bladder cancer	2.4e-05	0.000188	CcSEcCtD
Mesalazine—Constipation—Doxorubicin—urinary bladder cancer	2.39e-05	0.000187	CcSEcCtD
Mesalazine—Pain—Doxorubicin—urinary bladder cancer	2.39e-05	0.000187	CcSEcCtD
Mesalazine—Body temperature increased—Epirubicin—urinary bladder cancer	2.39e-05	0.000187	CcSEcCtD
Mesalazine—Abdominal pain—Epirubicin—urinary bladder cancer	2.39e-05	0.000187	CcSEcCtD
Mesalazine—Hypersensitivity—Methotrexate—urinary bladder cancer	2.38e-05	0.000186	CcSEcCtD
Mesalazine—Asthenia—Methotrexate—urinary bladder cancer	2.32e-05	0.000181	CcSEcCtD
Mesalazine—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.3e-05	0.00018	CcSEcCtD
Mesalazine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.29e-05	0.000179	CcSEcCtD
Mesalazine—Pruritus—Methotrexate—urinary bladder cancer	2.28e-05	0.000179	CcSEcCtD
Mesalazine—Hypersensitivity—Epirubicin—urinary bladder cancer	2.23e-05	0.000174	CcSEcCtD
Mesalazine—Urticaria—Doxorubicin—urinary bladder cancer	2.22e-05	0.000174	CcSEcCtD
Mesalazine—Abdominal pain—Doxorubicin—urinary bladder cancer	2.21e-05	0.000173	CcSEcCtD
Mesalazine—Body temperature increased—Doxorubicin—urinary bladder cancer	2.21e-05	0.000173	CcSEcCtD
Mesalazine—Diarrhoea—Methotrexate—urinary bladder cancer	2.21e-05	0.000173	CcSEcCtD
Mesalazine—Asthenia—Epirubicin—urinary bladder cancer	2.17e-05	0.00017	CcSEcCtD
Mesalazine—Pruritus—Epirubicin—urinary bladder cancer	2.14e-05	0.000167	CcSEcCtD
Mesalazine—Dizziness—Methotrexate—urinary bladder cancer	2.14e-05	0.000167	CcSEcCtD
Mesalazine—Diarrhoea—Epirubicin—urinary bladder cancer	2.07e-05	0.000162	CcSEcCtD
Mesalazine—Hypersensitivity—Doxorubicin—urinary bladder cancer	2.06e-05	0.000161	CcSEcCtD
Mesalazine—Vomiting—Methotrexate—urinary bladder cancer	2.05e-05	0.000161	CcSEcCtD
Mesalazine—Rash—Methotrexate—urinary bladder cancer	2.04e-05	0.000159	CcSEcCtD
Mesalazine—Dermatitis—Methotrexate—urinary bladder cancer	2.03e-05	0.000159	CcSEcCtD
Mesalazine—Headache—Methotrexate—urinary bladder cancer	2.02e-05	0.000158	CcSEcCtD
Mesalazine—Asthenia—Doxorubicin—urinary bladder cancer	2.01e-05	0.000157	CcSEcCtD
Mesalazine—Dizziness—Epirubicin—urinary bladder cancer	2e-05	0.000156	CcSEcCtD
Mesalazine—Pruritus—Doxorubicin—urinary bladder cancer	1.98e-05	0.000155	CcSEcCtD
Mesalazine—Vomiting—Epirubicin—urinary bladder cancer	1.92e-05	0.00015	CcSEcCtD
Mesalazine—Nausea—Methotrexate—urinary bladder cancer	1.92e-05	0.00015	CcSEcCtD
Mesalazine—Diarrhoea—Doxorubicin—urinary bladder cancer	1.91e-05	0.00015	CcSEcCtD
Mesalazine—Rash—Epirubicin—urinary bladder cancer	1.91e-05	0.000149	CcSEcCtD
Mesalazine—Dermatitis—Epirubicin—urinary bladder cancer	1.9e-05	0.000149	CcSEcCtD
Mesalazine—Headache—Epirubicin—urinary bladder cancer	1.89e-05	0.000148	CcSEcCtD
Mesalazine—Dizziness—Doxorubicin—urinary bladder cancer	1.85e-05	0.000145	CcSEcCtD
Mesalazine—Nausea—Epirubicin—urinary bladder cancer	1.8e-05	0.00014	CcSEcCtD
Mesalazine—Vomiting—Doxorubicin—urinary bladder cancer	1.78e-05	0.000139	CcSEcCtD
Mesalazine—Rash—Doxorubicin—urinary bladder cancer	1.76e-05	0.000138	CcSEcCtD
Mesalazine—Dermatitis—Doxorubicin—urinary bladder cancer	1.76e-05	0.000138	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—FGFR3—urinary bladder cancer	1.75e-05	0.000192	CbGpPWpGaD
Mesalazine—Headache—Doxorubicin—urinary bladder cancer	1.75e-05	0.000137	CcSEcCtD
Mesalazine—CHUK—Signaling by NGF—EGFR—urinary bladder cancer	1.75e-05	0.000191	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—ERBB2—urinary bladder cancer	1.73e-05	0.00019	CbGpPWpGaD
Mesalazine—IKBKB—B Cell Activation—HRAS—urinary bladder cancer	1.73e-05	0.000189	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CREBBP—urinary bladder cancer	1.72e-05	0.000188	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IFNA2—urinary bladder cancer	1.71e-05	0.000187	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—MTHFR—urinary bladder cancer	1.71e-05	0.000187	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—NAT2—urinary bladder cancer	1.69e-05	0.000186	CbGpPWpGaD
Mesalazine—PTGS2—Disease—LIG1—urinary bladder cancer	1.68e-05	0.000185	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—KRAS—urinary bladder cancer	1.68e-05	0.000184	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.68e-05	0.000184	CbGpPWpGaD
Mesalazine—Nausea—Doxorubicin—urinary bladder cancer	1.66e-05	0.00013	CcSEcCtD
Mesalazine—CHUK—Signaling by NGF—KRAS—urinary bladder cancer	1.65e-05	0.000181	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CDH1—urinary bladder cancer	1.63e-05	0.000179	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.63e-05	0.000179	CbGpPWpGaD
Mesalazine—CHUK—Immune System—S100B—urinary bladder cancer	1.61e-05	0.000177	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—EGFR—urinary bladder cancer	1.58e-05	0.000173	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—NQO1—urinary bladder cancer	1.56e-05	0.000171	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CREBBP—urinary bladder cancer	1.56e-05	0.00017	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IFNA2—urinary bladder cancer	1.55e-05	0.00017	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—NCOR1—urinary bladder cancer	1.54e-05	0.000168	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—KRAS—urinary bladder cancer	1.52e-05	0.000167	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.51e-05	0.000166	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—KRAS—urinary bladder cancer	1.5e-05	0.000164	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.49e-05	0.000164	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TYMP—urinary bladder cancer	1.49e-05	0.000163	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—MMP9—urinary bladder cancer	1.49e-05	0.000163	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CDH1—urinary bladder cancer	1.48e-05	0.000162	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—S100B—urinary bladder cancer	1.46e-05	0.00016	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—RRM2—urinary bladder cancer	1.46e-05	0.00016	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.46e-05	0.00016	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—ERCC2—urinary bladder cancer	1.44e-05	0.000158	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RBX1—urinary bladder cancer	1.44e-05	0.000158	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—ERBB2—urinary bladder cancer	1.44e-05	0.000157	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.43e-05	0.000157	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.43e-05	0.000157	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—HRAS—urinary bladder cancer	1.43e-05	0.000156	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—EP300—urinary bladder cancer	1.41e-05	0.000154	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—HRAS—urinary bladder cancer	1.4e-05	0.000154	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PPARG—urinary bladder cancer	1.38e-05	0.000152	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—ERBB2—urinary bladder cancer	1.38e-05	0.000151	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—SRC—urinary bladder cancer	1.37e-05	0.00015	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.36e-05	0.000149	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ENO2—urinary bladder cancer	1.36e-05	0.000149	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—HPGDS—urinary bladder cancer	1.36e-05	0.000149	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TSC1—urinary bladder cancer	1.35e-05	0.000148	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.35e-05	0.000148	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.35e-05	0.000148	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NAT2—urinary bladder cancer	1.35e-05	0.000147	CbGpPWpGaD
Mesalazine—CHUK—Disease—NCOR1—urinary bladder cancer	1.34e-05	0.000147	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—CREBBP—urinary bladder cancer	1.33e-05	0.000146	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.32e-05	0.000145	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTT1—urinary bladder cancer	1.31e-05	0.000144	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RBX1—urinary bladder cancer	1.31e-05	0.000143	CbGpPWpGaD
Mesalazine—PPARG—Generic Transcription Pathway—MYC—urinary bladder cancer	1.3e-05	0.000143	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—ERBB2—urinary bladder cancer	1.3e-05	0.000143	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GSTP1—urinary bladder cancer	1.3e-05	0.000143	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.29e-05	0.000142	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—HRAS—urinary bladder cancer	1.29e-05	0.000142	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—JAG1—urinary bladder cancer	1.29e-05	0.000141	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ENO2—urinary bladder cancer	1.28e-05	0.000141	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—HRAS—urinary bladder cancer	1.27e-05	0.000139	CbGpPWpGaD
Mesalazine—CHUK—Disease—ERCC2—urinary bladder cancer	1.26e-05	0.000138	CbGpPWpGaD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.26e-05	0.000138	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—ERBB2—urinary bladder cancer	1.25e-05	0.000137	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CDKN1A—urinary bladder cancer	1.23e-05	0.000135	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TSC1—urinary bladder cancer	1.23e-05	0.000135	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—PTEN—urinary bladder cancer	1.22e-05	0.000134	CbGpPWpGaD
Mesalazine—PTGS2—Disease—RBX1—urinary bladder cancer	1.22e-05	0.000133	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—TYMS—urinary bladder cancer	1.21e-05	0.000133	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—ESR1—urinary bladder cancer	1.21e-05	0.000132	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—EGFR—urinary bladder cancer	1.2e-05	0.000132	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.2e-05	0.000131	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GSTM1—urinary bladder cancer	1.2e-05	0.000131	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—NCOR1—urinary bladder cancer	1.2e-05	0.000131	CbGpPWpGaD
Mesalazine—CHUK—Disease—MTHFR—urinary bladder cancer	1.18e-05	0.00013	CbGpPWpGaD
Mesalazine—CHUK—Disease—TERT—urinary bladder cancer	1.18e-05	0.000129	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CDKN1A—urinary bladder cancer	1.18e-05	0.000129	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PTEN—urinary bladder cancer	1.18e-05	0.000129	CbGpPWpGaD
Mesalazine—CHUK—Immune System—FGFR3—urinary bladder cancer	1.17e-05	0.000129	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—JAG1—urinary bladder cancer	1.17e-05	0.000128	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—EP300—urinary bladder cancer	1.17e-05	0.000128	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—RRM2—urinary bladder cancer	1.16e-05	0.000127	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—GPX1—urinary bladder cancer	1.14e-05	0.000125	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—TNF—urinary bladder cancer	1.14e-05	0.000125	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—SRC—urinary bladder cancer	1.14e-05	0.000125	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—KRAS—urinary bladder cancer	1.13e-05	0.000124	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ERCC2—urinary bladder cancer	1.12e-05	0.000123	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CDKN1A—urinary bladder cancer	1.11e-05	0.000122	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PTEN—urinary bladder cancer	1.11e-05	0.000122	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—NQO1—urinary bladder cancer	1.09e-05	0.00012	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—SRC—urinary bladder cancer	1.09e-05	0.00012	CbGpPWpGaD
Mesalazine—PTGS2—Disease—JAG1—urinary bladder cancer	1.09e-05	0.000119	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTGS2—urinary bladder cancer	1.09e-05	0.000119	CbGpPWpGaD
Mesalazine—CHUK—Disease—FGFR3—urinary bladder cancer	1.08e-05	0.000119	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ENO2—urinary bladder cancer	1.08e-05	0.000118	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—HPGDS—urinary bladder cancer	1.08e-05	0.000118	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.07e-05	0.000117	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CDKN1A—urinary bladder cancer	1.07e-05	0.000117	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PTEN—urinary bladder cancer	1.07e-05	0.000117	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—FGFR3—urinary bladder cancer	1.06e-05	0.000117	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.06e-05	0.000116	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—EP300—urinary bladder cancer	1.06e-05	0.000116	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—CREBBP—urinary bladder cancer	1.06e-05	0.000116	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—MTHFR—urinary bladder cancer	1.06e-05	0.000116	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTT1—urinary bladder cancer	1.04e-05	0.000114	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—S100B—urinary bladder cancer	1.04e-05	0.000114	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—SRC—urinary bladder cancer	1.03e-05	0.000113	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.03e-05	0.000113	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CREBBP—urinary bladder cancer	9.99e-06	0.000109	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—EGFR—urinary bladder cancer	9.96e-06	0.000109	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDH1—urinary bladder cancer	9.92e-06	0.000109	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—SRC—urinary bladder cancer	9.89e-06	0.000108	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—HRAS—urinary bladder cancer	9.64e-06	0.000106	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—EGFR—urinary bladder cancer	9.56e-06	0.000105	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PTEN—urinary bladder cancer	9.49e-06	0.000104	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—S100B—urinary bladder cancer	9.46e-06	0.000104	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—KRAS—urinary bladder cancer	9.4e-06	0.000103	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NCOR1—urinary bladder cancer	9.38e-06	0.000103	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.24e-06	0.000101	CbGpPWpGaD
Mesalazine—CHUK—Disease—CREBBP—urinary bladder cancer	9.22e-06	0.000101	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTP1—urinary bladder cancer	9.11e-06	9.99e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CREBBP—urinary bladder cancer	9.06e-06	9.93e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—EP300—urinary bladder cancer	9.05e-06	9.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—KRAS—urinary bladder cancer	9.03e-06	9.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—EGFR—urinary bladder cancer	9.03e-06	9.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDH1—urinary bladder cancer	8.99e-06	9.86e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	8.81e-06	9.66e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NQO1—urinary bladder cancer	8.67e-06	9.5e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—EGFR—urinary bladder cancer	8.67e-06	9.5e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—KRAS—urinary bladder cancer	8.53e-06	9.35e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NCOR1—urinary bladder cancer	8.51e-06	9.32e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—TYMS—urinary bladder cancer	8.47e-06	9.28e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTM1—urinary bladder cancer	8.37e-06	9.18e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—NCOR1—urinary bladder cancer	8.37e-06	9.18e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ERBB2—urinary bladder cancer	8.37e-06	9.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—RHOA—urinary bladder cancer	8.34e-06	9.15e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TERT—urinary bladder cancer	8.27e-06	9.06e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CREBBP—urinary bladder cancer	8.23e-06	9.02e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—KRAS—urinary bladder cancer	8.19e-06	8.98e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GPX1—urinary bladder cancer	8.02e-06	8.79e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—HRAS—urinary bladder cancer	7.99e-06	8.76e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NCOR1—urinary bladder cancer	7.94e-06	8.7e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ERCC2—urinary bladder cancer	7.87e-06	8.63e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—ERBB2—urinary bladder cancer	7.72e-06	8.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HRAS—urinary bladder cancer	7.68e-06	8.41e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FGFR3—urinary bladder cancer	7.59e-06	8.32e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ERBB2—urinary bladder cancer	7.59e-06	8.31e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL2—urinary bladder cancer	7.58e-06	8.31e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—urinary bladder cancer	7.55e-06	8.28e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TERT—urinary bladder cancer	7.5e-06	8.22e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERCC2—urinary bladder cancer	7.46e-06	8.18e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—MTHFR—urinary bladder cancer	7.4e-06	8.11e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ESR1—urinary bladder cancer	7.37e-06	8.08e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.34e-06	8.04e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HRAS—urinary bladder cancer	7.25e-06	7.95e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTP1—urinary bladder cancer	7.23e-06	7.93e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDKN1A—urinary bladder cancer	7.15e-06	7.84e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PTEN—urinary bladder cancer	7.13e-06	7.82e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MTHFR—urinary bladder cancer	7.01e-06	7.69e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7e-06	7.67e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TERT—urinary bladder cancer	6.99e-06	7.67e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HRAS—urinary bladder cancer	6.96e-06	7.63e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FGFR3—urinary bladder cancer	6.88e-06	7.54e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL2—urinary bladder cancer	6.87e-06	7.54e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EP300—urinary bladder cancer	6.8e-06	7.46e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—urinary bladder cancer	6.74e-06	7.38e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TYMS—urinary bladder cancer	6.72e-06	7.37e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ESR1—urinary bladder cancer	6.68e-06	7.32e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTM1—urinary bladder cancer	6.65e-06	7.28e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—NCOR1—urinary bladder cancer	6.65e-06	7.28e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—SRC—urinary bladder cancer	6.62e-06	7.25e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN1A—urinary bladder cancer	6.6e-06	7.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTEN—urinary bladder cancer	6.59e-06	7.22e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDKN1A—urinary bladder cancer	6.48e-06	7.11e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PTEN—urinary bladder cancer	6.47e-06	7.09e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CREBBP—urinary bladder cancer	6.46e-06	7.08e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FGFR3—urinary bladder cancer	6.42e-06	7.03e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IGF1—urinary bladder cancer	6.38e-06	6.99e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GPX1—urinary bladder cancer	6.36e-06	6.98e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EP300—urinary bladder cancer	6.28e-06	6.89e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—urinary bladder cancer	6.28e-06	6.88e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ERCC2—urinary bladder cancer	6.25e-06	6.85e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EP300—urinary bladder cancer	6.17e-06	6.76e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—SRC—urinary bladder cancer	6.11e-06	6.7e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARG—urinary bladder cancer	6e-06	6.58e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—SRC—urinary bladder cancer	6e-06	6.58e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTEN—urinary bladder cancer	5.88e-06	6.44e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—MTHFR—urinary bladder cancer	5.87e-06	6.44e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CREBBP—urinary bladder cancer	5.86e-06	6.42e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RHOA—urinary bladder cancer	5.84e-06	6.4e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGFR—urinary bladder cancer	5.8e-06	6.36e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IGF1—urinary bladder cancer	5.78e-06	6.34e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CREBBP—urinary bladder cancer	5.76e-06	6.32e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—EP300—urinary bladder cancer	5.6e-06	6.14e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KRAS—urinary bladder cancer	5.48e-06	6e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—urinary bladder cancer	5.47e-06	6e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CREBBP—urinary bladder cancer	5.46e-06	5.99e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ERBB2—urinary bladder cancer	5.41e-06	5.93e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGFR—urinary bladder cancer	5.35e-06	5.87e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RHOA—urinary bladder cancer	5.3e-06	5.81e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGFR—urinary bladder cancer	5.26e-06	5.76e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCL8—urinary bladder cancer	5.13e-06	5.62e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—KRAS—urinary bladder cancer	5.06e-06	5.54e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KRAS—urinary bladder cancer	4.97e-06	5.44e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—RHOA—urinary bladder cancer	4.94e-06	5.42e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ERBB2—urinary bladder cancer	4.9e-06	5.38e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL2—urinary bladder cancer	4.9e-06	5.37e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCND1—urinary bladder cancer	4.78e-06	5.24e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARG—urinary bladder cancer	4.76e-06	5.22e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—urinary bladder cancer	4.72e-06	5.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HRAS—urinary bladder cancer	4.66e-06	5.1e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCL8—urinary bladder cancer	4.65e-06	5.1e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP9—urinary bladder cancer	4.64e-06	5.09e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN1A—urinary bladder cancer	4.62e-06	5.07e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTEN—urinary bladder cancer	4.61e-06	5.06e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CREBBP—urinary bladder cancer	4.58e-06	5.02e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERBB2—urinary bladder cancer	4.58e-06	5.02e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL2—urinary bladder cancer	4.44e-06	4.87e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EP300—urinary bladder cancer	4.4e-06	4.82e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCND1—urinary bladder cancer	4.33e-06	4.75e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—HRAS—urinary bladder cancer	4.3e-06	4.71e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SRC—urinary bladder cancer	4.28e-06	4.69e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HRAS—urinary bladder cancer	4.22e-06	4.63e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP9—urinary bladder cancer	4.21e-06	4.61e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN1A—urinary bladder cancer	4.19e-06	4.59e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTEN—urinary bladder cancer	4.18e-06	4.58e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTEN—urinary bladder cancer	4.12e-06	4.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EP300—urinary bladder cancer	3.99e-06	4.37e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—EP300—urinary bladder cancer	3.93e-06	4.3e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN1A—urinary bladder cancer	3.91e-06	4.29e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PTEN—urinary bladder cancer	3.9e-06	4.28e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SRC—urinary bladder cancer	3.88e-06	4.25e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—urinary bladder cancer	3.83e-06	4.2e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGFR—urinary bladder cancer	3.75e-06	4.11e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EP300—urinary bladder cancer	3.72e-06	4.08e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SRC—urinary bladder cancer	3.62e-06	3.97e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KRAS—urinary bladder cancer	3.54e-06	3.88e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—urinary bladder cancer	3.48e-06	3.81e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGFR—urinary bladder cancer	3.4e-06	3.73e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PTEN—urinary bladder cancer	3.27e-06	3.58e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—urinary bladder cancer	3.24e-06	3.55e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KRAS—urinary bladder cancer	3.21e-06	3.52e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGFR—urinary bladder cancer	3.17e-06	3.48e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—urinary bladder cancer	3.15e-06	3.45e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—EP300—urinary bladder cancer	3.12e-06	3.42e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HRAS—urinary bladder cancer	3.01e-06	3.3e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KRAS—urinary bladder cancer	3e-06	3.28e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—urinary bladder cancer	2.85e-06	3.13e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HRAS—urinary bladder cancer	2.73e-06	2.99e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HRAS—urinary bladder cancer	2.55e-06	2.79e-05	CbGpPWpGaD
